These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 18955525)

  • 1. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection.
    Louie T; Miller M; Donskey C; Mullane K; Goldstein EJ
    Antimicrob Agents Chemother; 2009 Jan; 53(1):223-8. PubMed ID: 18955525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection.
    Sullivan KM; Spooner LM
    Ann Pharmacother; 2010 Feb; 44(2):352-9. PubMed ID: 20071495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection.
    Citron DM; Babakhani F; Goldstein EJ; Nagaro K; Sambol S; Sears P; Shue YK; Gerding DN
    Anaerobe; 2009 Dec; 15(6):234-6. PubMed ID: 19755166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection.
    Louie TJ; Emery J; Krulicki W; Byrne B; Mah M
    Antimicrob Agents Chemother; 2009 Jan; 53(1):261-3. PubMed ID: 18955523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.
    Miller M
    Expert Opin Pharmacother; 2010 Jun; 11(9):1569-78. PubMed ID: 20446864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection.
    Louie T; Nord CE; Talbot GH; Wilcox M; Gerding DN; Buitrago M; Kracker H; Charef P; Cornely OA
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6266-73. PubMed ID: 26248357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of vancomycin dose on treatment outcomes in severe Clostridium difficile infection.
    Lam SW; Bass SN; Neuner EA; Bauer SR
    Int J Antimicrob Agents; 2013 Dec; 42(6):553-8. PubMed ID: 24103633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fidaxomicin for the treatment of Clostridium difficile infections.
    Whitman CB; Czosnowski QA
    Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tigecycline for the treatment of severe Clostridium difficile infection.
    Larson KC; Belliveau PP; Spooner LM
    Ann Pharmacother; 2011 Jul; 45(7-8):1005-10. PubMed ID: 21730279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
    Cornely OA
    Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():28-35. PubMed ID: 23121552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clostridium difficile infection in older adults: a review and update on its management.
    Kee VR
    Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trial watch: Phase III success for novel Clostridium difficile antibiotic.
    Nat Rev Drug Discov; 2010 Apr; 9(4):260. PubMed ID: 20357795
    [No Abstract]   [Full Text] [Related]  

  • 13. Fidaxomicin: a new option for the treatment of Clostridium difficile infection.
    Johnson AP; Wilcox MH
    J Antimicrob Chemother; 2012 Dec; 67(12):2788-92. PubMed ID: 22865382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal systemic and high faecal exposure to cadazolid in patients with severe Clostridium difficile infection.
    Gehin M; Desnica B; Dingemanse J
    Int J Antimicrob Agents; 2015 Nov; 46(5):576-81. PubMed ID: 26419191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial.
    Lee CH; Patino H; Stevens C; Rege S; Chesnel L; Louie T; Mullane KM
    J Antimicrob Chemother; 2016 Oct; 71(10):2964-71. PubMed ID: 27432604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
    Lancaster JW; Matthews SJ
    Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection.
    Venugopal AA; Johnson S
    Clin Infect Dis; 2012 Feb; 54(4):568-74. PubMed ID: 22156854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of age on treatment outcomes in Clostridium difficile infection.
    Louie TJ; Miller MA; Crook DW; Lentnek A; Bernard L; High KP; Shue YK; Gorbach SL
    J Am Geriatr Soc; 2013 Feb; 61(2):222-30. PubMed ID: 23379974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection.
    Crowther GS; Baines SD; Todhunter SL; Freeman J; Chilton CH; Wilcox MH
    J Antimicrob Chemother; 2013 Jan; 68(1):168-76. PubMed ID: 22966180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection.
    Brandt LJ; Aroniadis OC; Mellow M; Kanatzar A; Kelly C; Park T; Stollman N; Rohlke F; Surawicz C
    Am J Gastroenterol; 2012 Jul; 107(7):1079-87. PubMed ID: 22450732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.